RxDoctor Payments Data

Brian Miller, MD

Psychiatry · la Mesa, CANPI 1861411381

Payments from drug & device makers

$146,978in general payments, 2019–2025

Across 299 payments — averaging $491.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$129K
  • Johnson & Johnson$5K
  • E.r. Squibb & Sons, L.L.C.$4K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
  • Otsuka America Pharmaceutical, Inc.$3K
  • GSK$567
  • plus $2K from 11 others

What the payments were for

  • Consulting fees$15,44111%
  • Speaking & faculty fees$114,77878%
  • Travel & lodging$6,6105%
  • Food & beverage$9,6107%
  • Education$250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$146,978 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$128,163
Medicare patients
106
Services billed
1,311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate77$281,257
SpravatoEsketamine Hcl36$212,386
AristadaAripiprazole Lauroxil49$167,973
FanaptIloperidone44$167,296
LybalviOlanzapine/Samidorphan Malate58$97,877
UzedyRisperidone20$59,347
Chlorpromazine Hcl59$41,227
Clozapine479$35,398
Lurasidone Hcl151$35,349
Olanzapine OdtOlanzapine97$17,315
Divalproex Sodium177$16,915
Olanzapine363$15,536
Paliperidone ErPaliperidone63$12,893
VraylarCariprazine Hcl18$12,413
Haloperidol133$9,790

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Spravato$4,988$493,642113 claims
Alkermes, Inc.Aristada, Lybalvi$128,716$265,851107 claims
Vanda Pharmaceuticals Inc.Fanapt$279$167,29644 claims
Teva Pharmaceuticals USA, Inc.Uzedy$129$59,34720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.

Other psychiatry in la Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →